NCT01783171 - Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2013

Primary Completion Date

July 12, 2016

Study Completion Date

July 12, 2016

Conditions

Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage III Pancreatic Cancer AJCC v6 and v7Stage IV Pancreatic Cancer AJCC v6 and v7Unresectable Pancreatic Carcinoma

Interventions

DRUG

Akt Inhibitor MK2206

Given PO

DRUG

Dinaciclib

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (5)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

53792

University of Wisconsin Hospital and Clinics, Madison

80045

University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora

80217-3364

University of Colorado, Denver

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH